Celcuity
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celcuity and other ETFs, options, and stocks.About CELC
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies.
CEOBrian F. Sullivan
CEOBrian F. Sullivan
Employees87
Employees87
HeadquartersMinneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded2012
Founded2012
Employees87
Employees87
CELC Key Statistics
Market cap2.27B
Market cap2.27B
Price-Earnings ratio-14.86
Price-Earnings ratio-14.86
Dividend yield—
Dividend yield—
Average volume986.63K
Average volume986.63K
High today$54.06
High today$54.06
Low today$50.10
Low today$50.10
Open price$51.54
Open price$51.54
Volume517.85K
Volume517.85K
52 Week high$55.44
52 Week high$55.44
52 Week low$7.58
52 Week low$7.58
CELC News
TipRanks 2d
Celcuity Inc. Earnings Call: Clinical Progress and Financial FortificationCelcuity Inc. ((CELC)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks P...
TipRanks 6d
Celcuity’s Gedatolisib Gains Momentum with FDA’s RTOR Program and Promising Phase 3 Trial ResultsIn a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Celcuity, with a price target of $65.00. Elevate Your Investing Stra...
TipRanks 6d
Celcuity to initiate gedatolisib NDA submissionCelcuity (CELC) announced the FDA agreed to accept its new drug application for gedatolisib in HR+/HER2- advanced breast cancer for review under the Real-Time O...
Analyst ratings
100%
of 8 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.